Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | PARP1 | P09874 | 2/20 | 0.49 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paliroden SCHEMBL4587135 | 1.00 | HTR7 (0.53) | HTR7PPARGPPARASIGMAR1PARP1 | |
| SCHEMBL4587500 | 0.97 | HTR7 (0.52) | HTR7PPARGPPARASIGMAR1PARP1 | |
| Hydrochloric Acid SCHEMBL7393191 | 0.95 | MAOB (0.53) | HTR7PPARGPPARASIGMAR1PARP1 | |
| SCHEMBL9501239 | 0.95 | SIGMAR1 (0.55) | HTR7PPARGPPARASIGMAR1PARP1 | |
| Hydrochloric Acid SCHEMBL9485989 | 0.94 | SIGMAR1 (0.54) | HTR7PPARGPPARASIGMAR1PARP1 | |
| SCHEMBL4589037 | 0.93 | HTR7 (0.52) | HTR7PPARGPPARASIGMAR1PARP1 | |
| SCHEMBL4587555 | 0.93 | HTR7 (0.54) | HTR7PPARGPPARASIGMAR1PARP1 | |
| Hydrochloric Acid SCHEMBL7385918 | 0.92 | HTR7 (0.53) | HTR7PPARGPPARASIGMAR1PARP1 | |
| SCHEMBL4589363 | 0.92 | PPARG (0.51) | HTR7PPARGPPARASIGMAR1PARP1 | |
| SCHEMBL4589848 | 0.92 | SIGMAR1 (0.55) | HTR7PPARGPPARASIGMAR1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2024191125-A1 | METHOD FOR ACTIVATING ENDOGENOUS NEURAL STEM CELLS THROUGH LOW-INTENSITY FOCUSED ULTRASOUND TREATMENT | 연세대학교 산학협력단 | 2024-09-19 | — | — | WO | claimed |
| US-20250344963-A1 | METHODS FOR ACQUIRING AND ANALYZING NEUROMELANIN-SENSITIVE MRI | UNIV OF OTTAWA INSTITUTE OF MENTAL HEALTH RESEARCH (CA) | 2025-11-13 | — | — | US | disclosed |
| US-20250195477-A1 | DEUTERATED IDAZOXAN AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC. | 2025-06-19 | — | — | US | disclosed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| EP-4545066-A2 | 4-PHENYL-TETRAHYDROPYRIDINE DERIVATIVES FOR TREATING HEARING DISEASES | Cilcare Dev (FR) | 2025-04-30 | — | — | EP | disclosed |
| EP-4479365-A1 | DEUTERATED IDAZOXAN AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-119053573-A | Deuterated imidazole kesheng and methods of use thereof | 人类生物科学股份有限公司 | 2024-11-29 | — | — | CN | disclosed |
| WO-2024211430-A2 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-10-10 | — | — | WO | disclosed |
| CN-115645389-B | Application of compound ML1 and derivative thereof in improving activity and function of cerebral cortex | 刘晓栋 | 2024-10-01 | — | — | CN | disclosed |
| CN-118715014-A | 4-Phenyl-tetrahydropyridine derivatives for the treatment of hearing disorders | 西尔卡雷德夫公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-115087665-A | Engineered platelets for targeted delivery of therapeutic agents | JPV01有限公司 | 2022-09-20 | — | — | CN | disclosed |
| EP-3368040-B1 | METHODS AND COMPOSITIONS FOR RECOVERY FROM STROKE | EIP PHARMA LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20220251165-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-08-11 | — | — | US | disclosed |
| EP-4026898-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-07-13 | — | — | EP | disclosed |
| US-20220168243-A1 | CORONAVIRUS TREATMENT COMPOSITIONS AND METHODS | UNIV NEW YORK STATE RES FOUND (US) | 2022-06-02 | — | — | US | disclosed |
| US-11291670-B2 | Therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of angiogenesis | PHARNEXT (FR) | 2022-04-05 | — | — | US | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| CN-114010641-A | Methods for treating neurological disorders | 爱普制药有限责任公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168243-A1 | CORONAVIRUS TREATMENT COMPOSITIONS AND METHODS | ACE, SARS1, ACE2 | HTR7 3915/4885PPARG 3153/4885PPARA 2762/4885 |
| US-20250195477-A1 | DEUTERATED IDAZOXAN AND METHODS OF USE THEREOF | XDH, INA, SLC6A3 | HTR7 38/4885PPARG 565/4885PPARA 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.